期刊文献+

沙培林膀胱灌注的临床观察及实验研究 被引量:1

Study of intravesical instillation with sapylin on the clinical observation and animal experiment
暂未订购
导出
摘要 目的初步探索沙培林膀胱灌注治疗的安全性、有效性和作用机制。方法 (1)临床研究:收集膀胱肿瘤术后行沙培林膀胱灌注治疗的患者40例,检测灌注前后尿液中细胞因子IL-2、TNF-α、INF-γ的含量,术后6个月复查膀胱镜。(2)动物实验:取雌性大鼠75只,分为空白对照组(15只)、生理盐水灌注组(15只)、沙培林灌注组(15只)、BCG灌注组(15只)和大肠杆菌灌注组(15只),每周灌注治疗一次,6周后停止灌注。从每组中随机选取10只大鼠,处死后取其膀胱三角区组织做病理切片,观察并比较免疫细胞浸润情况,同时行免疫组化分析,检测IL-2、TNF-α、INF-γ在组织中的表达情况。剩余25只大鼠不做任何处理,饲养2个月后全部处死,取其膀胱三角区组织做病理切片,观察停止灌注后膀胱组织是否出现慢性炎性改变。结果 (1)临床研究:膀胱肿瘤术后膀胱灌注沙培林,尿中细胞因子IL-2、TNF-α、INF-γ均显著升高。6个月后复查膀胱镜见炎性改变且均未见肿瘤复发,不良反应发生率低。(2)动物实验:膀胱灌注6周后大鼠膀胱免疫细胞浸润情况与细胞因子IL-2、TNF-α、INF-γ的表达相似:大肠杆菌组>沙培林组≈BCG组>生理盐水组>空白对照组;停止膀胱灌注2个月后,大肠杆菌组表现为膀胱炎性改变,其余各组几乎均表现为正常尿路上皮。结论沙培林与BCG等免疫调节剂作用机制相似,通过引起膀胱上皮炎性反应,增强病变部位的免疫功能,从而识别并清除变异细胞,且在一段时间后能自行恢复为正常尿路上皮,不引起慢性炎性改变,沙培林是一种安全、有效的免疫调节剂。 Objective To investigate the efficacy,safety and the mechanism of intravesical instillation of OK-432(sapylin)by the clinical observation and animal's experiment. Methods(1)Clinical research:40cases diagnosed with bladder tumor which used OK-432(sapylin)for intravesical instillation in the postoperative period were collected,and determing the content of cytokine TNF-α,INF-γand IL-2in the urine collected before and after infusion respectively,reviewing the cystoscopy 3months after operation,and counting the adverse effects.(2)Animal experiment:divided75female rats into five groups:blank control group(15),saline perfusion group(15),sapylin perfusion group(15),BCG vaccine perfusion group(15),E.coli perfusion group(15),perfusion treatment once a week,continuous 6weeks,then selected 10 rats from each group randomly,killed the rats and took the trigone tissue for pathological salices and immunohistochemical analysis of cytokine TNF-α,INF-γand IL-2.The rest 25 rats just raised after 2 months without any treatment,after 2months killed the rest rats and took the trigone tissue for pathological salices. Results(1)Clinical research:the content of urine cytokine TNF-α,INF-γand IL-2,after perfusion of OK-432(sapylin)rose significantly,after 6months reviewed the cystoscopy and reported inflammatory changes,no tumor recurrence,and low incidence of adverse reactions.(2)Animal experiment:after 6weeks intravesical instillation with different solutions,infiltration of immune cell in the rat bladder tissue and expression of cytokines TNF-α,INF-γand IL-2were similar:E.coli group sapylin group ≈BCG group saline group blank control group;stopped perfusion 2 months was shown as:E.coli group characterized by bladder inflammatory change,almost all the rest of the group was turn to normal transitional epithelium.Conclusions Sapylin's action mechanism is similar with BCG,mainly through activating the bladder epithelial inflammatory reaction enhance the immune function of the lesion site,and than recognize and eliminate the mutant cells,and can recover to normal transitional epithelium after a period of time,therefore sapylin is a kind of safe and effective immune regulator.
出处 《现代泌尿生殖肿瘤杂志》 2016年第6期345-349,共5页 Journal of Contemporary Urologic and Reproductive Oncology
关键词 沙培林 膀胱灌注 膀胱肿瘤 细胞因子 Sapylin Intravesical instillation Bladder tumor Cytokines
  • 相关文献

参考文献2

二级参考文献15

  • 1梁荣江,辛业宏.沙培林膀胱内灌注预防浅表性膀胱癌术后复发[J].齐齐哈尔医学院学报,2006,27(8):923-924. 被引量:4
  • 2袁润强,霍淑芬,李志坚,丘少鹏.沙培林膀胱灌注预防浅表性膀胱癌术后复发近期疗效观察和经验总结[J].中国肿瘤临床与康复,2006,13(5):442-444. 被引量:5
  • 3Nieder A M, Simon M A, Kim S S, et al . Radical cystectomy after bacillus Calmetter- Guerin for highrisk Ta ,T1 , and carcinoma in situ: defining the risk of initial bladder preservation [J]. Urology, 2006, 67 (4): 737- 741.
  • 4Nakayama F, Iwagaki H, Gouchi A, et al . Effect of streptococcal lyzate OK-432 on peripheral blood mono nuclear cells in gastric cancer patients [J].J Med, 1998,29(1): 199--215.
  • 5Yamaguchi Y, Miyahara E, Ohshita A, et al . locore gional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK- 432 plus interleukin-2 induction of autologous tumor reactive CD4^+ Th1 killer lymphocytes [J]. Br J Cancer, 2003, 89:1876- 1884.
  • 6吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004.589-591.
  • 7Jemal A, Sieqel R, Ward E, et al. Cancer statistics, 2009 [J]. CA Cancer J Clin,2009,59(4) :225-249.
  • 8Sylvester RJ. Natural history, recurrence and progression in superficial bladder cancer[J]. ScientificWorldJournal, 2006, 6 :2617-2625.
  • 9Schenk-Braat EA,Bangma CH. Immunotherapy for superfi-cial bladder cancer[J]. Cancer Immunol Imnmnother, 2005, 54(5) :414-423.
  • 10Patankar S, Jamkar A, Dobhada S, et al. PlasmaKinetie su- perpulse transurethral resection versus conventional tran- surethral resection of prostate[J]. J Endourol, 2006,20 (2) : 215-219.

共引文献16

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部